Early use of statins in acute coronary syndromes

被引：18

作者：

Joshua M. Spin

Randall H. Vagelos

机构：

[1] Stanford University Medical Center, Flak CVRB-279, Stanford

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 1期

关键词：

Statin; Acute Coronary Syndrome; Simvastatin; Pravastatin; Statin Therapy;

D O I：

10.1007/s11883-003-0068-0

中图分类号：

学科分类号：

摘要：

This review examines the use of statin medications early in the clinical course of acute coronary syndrome (ACS). Available data demonstrate that there are clear clinical benefits to this practice. Numerous previous studies have documented the primary and secondary benefits of statins in the prevention of coronary events. Recent trials show that when statins are used during hospital admissions for ACS, patients experience decreased recurrent myocardial infarction, lower death rates, and fewer repeat hospitalizations for ischemia or revascularization. Several studies suggest that the positive effects of statins on plaque stabilization, inflammation, thrombosis, and endothelial function may be independent of lipid levels. There is also an emerging view that beneficial lipid-lowering with statins in high-risk patients has no lower limit. This information suggests that all patients admitted for ACS should be treated with statins, regardless of cholesterol levels. Copyright © 2003 by Current Science Inc.

引用

页码：44 / 51

页数：7

共 60 条

[1]

Braunwald E., Antman E.M., Beasley J.W., Et al., ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines, Circulation, 102, pp. 1193-1209, (2000)

[2]

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)

[3]

Fonarow G.C., Ballantyne C.M., In-hospital initiation of lipid lowering therapy for patients with coronary heart disease: The time is now, Circulation, 103, (2001)

[4]

Acevedo M., Sprecher D.L., Statins in acute coronary syndromes: Start them in the hospital, Cleveland Clin. J. Med., 69, pp. 25-37, (2002)

[5]

Libby P., Ridker P.M., Maseri A., Inflammation and atherosclerosis, Circulation, 105, pp. 1135-1143, (2002)

[6]

Yamada D.M., Topol E.J., Importance of microembolization and inflammation in atherosclerotic heart disease, Am. Heart J., 140, (2000)

[7]

Libby P., Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, pp. 365-372, (2001)

[8]

Kinlay S., Ganz P., Relation between endothelial dysfunction and the acute coronary syndrome: Implications for therapy, Am. J. Cardiol., 86 S, (2000)

[9]

Kalinowski L., Dobrucki L., Brovkovych V., Et al., Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin, Circulation, 105, pp. 933-938, (2002)

[10]

Wilson S.H., Simari R.D., Best P.J.M., Et al., Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering, Arterioscler. Thromb. Vasc. Biol., 21, pp. 122-128, (2001)

← 1 2 3 4 5 6 →